Female Physicians Found More Likely to Leave Rural Practice

This article originally appeared here.
Share this content:
Female Physicians Found More Likely to Leave Rural Practice
Female Physicians Found More Likely to Leave Rural Practice

MONDAY, July 17, 2017 (HealthDay News) -- Factors associated with physician mobility include smaller population size and lower primary care physician supply, according to a study published online in the July/August issue of the Annals of Family Medicine.

Matthew R. McGrail, Ph.D., from Monash University in Churchill, Australia, and colleagues created seven two-year mobility periods during 2000 to 2014 using data for each clinically-active U.S. physician. The periods were merged with county-level rurality, physician supply, economic characteristics, demographic measures, and individual physician characteristics.

The researchers found that biennial turnover was about 17 and 9 percent for physicians aged 45 years and younger and for those aged 46 to 65 years, respectively; little difference was seen between rural and metropolitan groups. Counties that lacked a hospital, those with a smaller population size, and those with lower primary care physician supply had higher county-level physician mobility, while there was little effect for area-level economic and demographic factors. The likelihood of leaving rural practice was higher for female physicians (odds ratios, 1.24 and 1.46 for those aged 45 years or younger and those aged 46 to 65 years, respectively) and for those born in a metropolitan area (odds ratios, 1.75 and 1.56, respectively).

"Rural health workforce planners and policymakers must be cognizant of these key factors to more effectively target retention policies and to take into account the additional support needed by these more vulnerable communities," the authors write.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths